Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | MEDI5752 |
Trade Name | |
Synonyms | MEDI-5752|MEDI 5752 |
Drug Descriptions |
MEDI5752 is a bispecific human IgG1 monoclonal antibody that binds PD1 (PDCD1) and CTLA4, potentially resulting in enhanced anti-tumor immune response (Cancer Res 2018;78(13 Suppl):Abstract nr 2776). |
DrugClasses | CTLA4 Antibody 24 Immune Checkpoint Inhibitor 151 PD-L1/PD-1 antibody 98 |
CAS Registry Number | NA |
NCIT ID | C171937 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Axitinib + MEDI5752 | Axitinib MEDI5752 | 0 | 1 |
Capecitabine + MEDI5752 + Oxaliplatin | Capecitabine MEDI5752 Oxaliplatin | 0 | 1 |
Carboplatin + MEDI5752 + Pemetrexed Disodium | Carboplatin MEDI5752 Pemetrexed Disodium | 0 | 1 |
Fluorouracil + Leucovorin + MEDI5752 + Oxaliplatin | Fluorouracil Leucovorin MEDI5752 Oxaliplatin | 0 | 1 |
MEDI5752 | MEDI5752 | 0 | 1 |